Evidence map›Paper›PMID 31836624›Full record

ArticleMolecular pharmacology2020

hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II

Evan E Kania, Jessika Carvajal-Moreno, Victor A Hernandez, Anthony English, Jonathan L Papa, Nicholas Shkolnikov, Hatice Gulcin Ozer, Ayse Selen Yilmaz, Jack C Yalowich, Terry S Elton

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Circumvention of Topoisomerase IIMolecular pharmacology · 2024
    Article
  3. Article
  4. Article
  5. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase IIThe Journal of pharmacology and experimental therapeutics · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Evan E KaniaDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Jessika Carvajal-MorenoDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Victor A HernandezDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Anthony EnglishDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Jonathan L PapaDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Nicholas ShkolnikovDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Hatice Gulcin OzerDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Ayse Selen YilmazDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio.
Jack C YalowichDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio yalowich.1@osu.edu.
Terry S EltonDivision of Pharmaceutics and Pharmacology, College of Pharmacy (E.E.K., J.C.-M., V.A.H., A.E., J.L.P., N.S., J.C.Y., T.S.E.) and Department of Biomedical Informatics, College of Medicine (H.G.O., A.S.Y.), The Ohio State University, Columbus, Ohio elton.8@osu.edu.
The Ohio State University · US

Funding

Novel Topoisomerase II alpha isoform as a drug resistance determinantR01CA226906 · NCI · OHIO STATE UNIVERSITY · PI ELTON, TERRY S, YALOWICH, JACK C. · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA226906
6 · The paper itself

Abstract

DNA topoisomerase II

Indexed as

Antineoplastic Agents, PhytogenicDNA Topoisomerases, Type IIDose-Response Relationship, DrugDrug Resistance, NeoplasmEtoposideHumansK562 CellsMicroRNAsTranscription, GeneticAntineoplastic Agents, PhytogenicDNA Topoisomerases, Type IIEtoposideMicroRNAsMIRN93 microRNA, humanMIRN95 microRNA, human

Identifiers

PMID31836624
PMCPMC6978698
OpenAlexW2998681710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.